Company intelligence / Profile preview
BioStratum Inc.
Durham, North Carolina, United Statesbiostratum.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Other
01
Overview
BioStratum has pioneered research into basal lamina-targeted therapies for kidney disease, cancer, autoimmune diseases, and diabetes complications. Its pipeline includes several preclinical programs targeting metabolic and renal indications. The company has made significant scientific contributions but does not appear to have advanced any drug candidates beyond preclinical development as of the latest public information.
- Therapeutic areas
- OncologyImmunologyEndocrinologyNephrology
- Modalities
- Small molecule drugsChemical drugsBiological products
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on BioStratum Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioStratum Inc..